Prognostic value of monitoring a candidate immunophenotypic leukemic stem/progenitor cell population in patients allografted for acute myeloid leukemia
暂无分享,去创建一个
P. Vyas | C. Bradbury | C. Craddock | J. Khan | S. Nagra | J. Ward | N. Khan | N. Russell | S. Akiki | D. Grimwade | M. Griffiths | S. Freeman | R. Hills | A. Burnett | R. Gregg | A. Houlton | M. Rindl | Naeem Khan | Charlotte Bradbury | David Grimwade | Charles Craddock | Sandeep Nagra | Aimee E Houlton | Susanna Akiki | Richard Gregg | Max Rindl | Josephine Khan | Janice Ward | Mike Griffiths | Robert Hills | Alan Burnett | Nigel Russell | Paresh Vyas | Sylvie D. Freeman
[1] D. Grimwade,et al. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? , 2014, Blood.
[2] W. Hiddemann,et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] C. Craddock. Pharmacological methods to reduce disease recurrence. , 2013, Hematology. American Society of Hematology. Education Program.
[4] I. Weissman,et al. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia , 2013, Leukemia.
[5] E. Estey. How to manage high-risk acute myeloid leukemia , 2012, Leukemia.
[6] B. Seliger,et al. Clonal Evolution Including Partial Loss of Human Leukocyte Antigen Genes Favoring Extramedullary Acute Myeloid Leukemia Relapse After Matched Related Allogeneic Hematopoietic Stem Cell Transplantation , 2012, Transplantation.
[7] N. Kröger,et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. , 2012, Blood.
[8] P. Vyas,et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. , 2011, Cancer cell.
[9] M. Carroll,et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. , 2011, The Journal of clinical investigation.
[10] J. Gribben,et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. , 2010, Blood.
[11] F. Appelbaum. Optimising the conditioning regimen for acute myeloid leukaemia. , 2009, Best practice & research. Clinical haematology.
[12] เอกรัฐ รัฐฤทธิ์ธำรง. Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation , 2009 .
[13] J. Dick,et al. Stem cell concepts renew cancer research. , 2008, Blood.
[14] G. Schuurhuis,et al. Aberrant marker expression patterns on the CD34+CD38− stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission , 2007, Leukemia.
[15] D. Olive,et al. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. , 2000, Cancer research.